Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2)
β Scribed by Kenneth G. Hadlock; Robert Gish; Judy Rowe; Sonal S. Rajyaguru; Margaret Newsom; Ann Warford; Steven K.H. Foung
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 135 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0146-6615
- DOI
- 10.1002/jmv.1096
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The genotype of hepatitis C virus (HCV) can profoundly affect the success of antiviral therapy for HCV infection. A possible contributing factor is a varied immune response elicited by infection with different HCV genotypes. In this study, fullβlength E2 proteins of HCV genotypes 1a, 1b, 2a, and 2b were used to determine the fraction of the humoral immune response to HCV E2 that is genotype specific. Greater than 90% of all infected individuals had serum antibodies to the four E2 proteins. Overall, individuals infected with genotype 1a or 1b were characterized by variable immune responses to HCV E2 with relatively high amounts of crossβreactivity with other E2 proteins. Individuals infected with genotype 2a or 2b exhibited a strong preferential reactivity to genotype 2a and 2b E2 proteins. Individuals with elevated titers to HCV E2 were more likely to be infected with genotype 2a and had a significantly lower median viral load. These findings indicate that the antibody response to HCV E2 is affected by the genotype of the virus and that induction of a strong humoral immune response to HCV E2 may contribute to a decreased viral load. J. Med. Virol. 65:23β29, 2001. Β© 2001 WileyβLiss, Inc.
π SIMILAR VOLUMES
Active and/or passive immunoprophylaxis against hepatitis C virus (HCV) remain unachieved goals. Monoclonal antibodies might provide one approach to protection. We derived human monoclonal antibodies from the bone marrow of a patient with a well-controlled HCV infection of 22 years duration. Five di
trast, only a minor proportion of HCV RNA posi-A small proportion of patients with chronic hepative patients, but anti-HCV seronegative by comtitis C virus (HCV) infection show no serological mercial immunoassays, have humoral immune responses to the HCV polypeptides incorporated responses to the HC
## Abstract The molecular basis of antibody neutralization against hepatitis C virus (HCV) is poorly understood. The E2 glycoprotein of HCV is critically involved in viral infectivity through specific binding to the principal virus receptor component CD81, and is targeted by antiβHCV neutralizing a